BR112012023539A2 - Composto de indazol tricíclico, método para preparar o mesmo, intermediário, composição farmacêutica, e, uso do composto de indazol tricíclico - Google Patents

Composto de indazol tricíclico, método para preparar o mesmo, intermediário, composição farmacêutica, e, uso do composto de indazol tricíclico

Info

Publication number
BR112012023539A2
BR112012023539A2 BR112012023539A BR112012023539A BR112012023539A2 BR 112012023539 A2 BR112012023539 A2 BR 112012023539A2 BR 112012023539 A BR112012023539 A BR 112012023539A BR 112012023539 A BR112012023539 A BR 112012023539A BR 112012023539 A2 BR112012023539 A2 BR 112012023539A2
Authority
BR
Brazil
Prior art keywords
indazole compound
tricyclic indazole
preparing
pharmaceutical composition
tricyclic
Prior art date
Application number
BR112012023539A
Other languages
English (en)
Inventor
Alessandra Alisi Maria
Cazzolla Nicola
Furlotti Guido
Garrone Beatrice
Magaro Gabriele
Mangano Giorgina
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of BR112012023539A2 publication Critical patent/BR112012023539A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSTO DE INDAZOL TRICÍCLICO, MÉTODO PARA PREPARAR O MESMO, INTERMEDIÁRIO, COMPOSIÇÃO FARMACÊUTICA, E, USO DO COMPOSTO DE INDAZOL TRICÍCLICO. O composto de indazol tricíclico e seus sais farmaceuticamente aceitáveis de adição de ácido, seu uso, método e intermediários para prepará-los e um composição farmacêutica que os contenha. O composto de indazol tricíclico tem a seguinte fórmula geral (I), em que R1, R2, L2, X1, X2, X3, X4, X5, Y, W, m e n têm os significados estabelecidos na descrição.
BR112012023539A 2010-04-08 2011-03-04 Composto de indazol tricíclico, método para preparar o mesmo, intermediário, composição farmacêutica, e, uso do composto de indazol tricíclico BR112012023539A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10159346 2010-04-08
PCT/EP2011/053270 WO2011124430A1 (en) 2010-04-08 2011-03-04 Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it

Publications (1)

Publication Number Publication Date
BR112012023539A2 true BR112012023539A2 (pt) 2017-10-03

Family

ID=42664839

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012023539A BR112012023539A2 (pt) 2010-04-08 2011-03-04 Composto de indazol tricíclico, método para preparar o mesmo, intermediário, composição farmacêutica, e, uso do composto de indazol tricíclico

Country Status (26)

Country Link
US (2) US9120801B2 (pt)
EP (1) EP2556074B1 (pt)
JP (1) JP5739980B2 (pt)
KR (1) KR20130045239A (pt)
CN (1) CN102812028B (pt)
AR (1) AR080835A1 (pt)
AU (1) AU2011238054B2 (pt)
BR (1) BR112012023539A2 (pt)
CA (1) CA2788762C (pt)
CY (1) CY1116246T1 (pt)
DK (1) DK2556074T3 (pt)
EA (1) EA021417B1 (pt)
ES (1) ES2532534T3 (pt)
GE (1) GEP20135997B (pt)
HK (1) HK1179962A1 (pt)
HR (1) HRP20150325T1 (pt)
IL (1) IL221244A (pt)
MX (1) MX2012011231A (pt)
PL (1) PL2556074T3 (pt)
PT (1) PT2556074E (pt)
RS (1) RS53859B1 (pt)
SG (1) SG183168A1 (pt)
SI (1) SI2556074T1 (pt)
SM (1) SMT201500066B (pt)
UA (1) UA108747C2 (pt)
WO (1) WO2011124430A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016201649A (ja) * 2015-04-09 2016-12-01 キヤノン株式会社 撮像装置、撮像システム、および撮像装置の駆動方法
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
CN109336890B (zh) * 2018-11-17 2020-03-20 重庆文理学院 一种吲唑类衍生物的合成方法及抗肿瘤应用
US20220185812A1 (en) * 2019-03-13 2022-06-16 The Rockefeller University INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360819A1 (en) * 2001-12-28 2003-07-24 Bayer Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
DE102004054665A1 (de) * 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
ITMI20062230A1 (it) 2006-11-22 2008-05-23 Acraf Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende

Also Published As

Publication number Publication date
CN102812028B (zh) 2014-11-12
JP2013523790A (ja) 2013-06-17
ES2532534T3 (es) 2015-03-27
JP5739980B2 (ja) 2015-06-24
CA2788762A1 (en) 2011-10-13
IL221244A (en) 2016-02-29
US9120801B2 (en) 2015-09-01
AU2011238054A1 (en) 2012-08-23
CN102812028A (zh) 2012-12-05
HRP20150325T1 (hr) 2015-04-24
EA021417B1 (ru) 2015-06-30
MX2012011231A (es) 2012-11-12
HK1179962A1 (en) 2013-10-11
AU2011238054B2 (en) 2016-06-23
SI2556074T1 (sl) 2015-04-30
WO2011124430A1 (en) 2011-10-13
RS53859B1 (en) 2015-08-31
EP2556074B1 (en) 2015-01-21
CY1116246T1 (el) 2017-04-26
DK2556074T3 (en) 2015-03-23
CA2788762C (en) 2018-04-10
US20150320763A1 (en) 2015-11-12
SMT201500066B (it) 2015-05-05
US9655906B2 (en) 2017-05-23
EA201291014A1 (ru) 2013-03-29
PL2556074T3 (pl) 2015-06-30
GEP20135997B (en) 2013-12-25
UA108747C2 (uk) 2015-06-10
SG183168A1 (en) 2012-09-27
US20130023524A1 (en) 2013-01-24
EP2556074A1 (en) 2013-02-13
KR20130045239A (ko) 2013-05-03
PT2556074E (pt) 2015-03-04
AR080835A1 (es) 2012-05-09
IL221244A0 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
BR112012023539A2 (pt) Composto de indazol tricíclico, método para preparar o mesmo, intermediário, composição farmacêutica, e, uso do composto de indazol tricíclico
CR20120427A (es) Derivados de pirazol como inhibidores de jak
DOP2010000387A (es) Compuestos pirazolicos 436
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
BR112015014222A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
CR20120634A (es) Derivados de heteroaril imidazolona como inhibidores de jak
UY32203A (es) Amino pirimidinas y su uso en terapia
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY30759A1 (es) Compuestos quimicos
BR112012018695A2 (pt) compostos pirazol como antagonistas crth2
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY31865A (es) Derivados de urea heterocíclicos y métodos para la utilización de los mismos
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
CL2012001641A1 (es) Compuestos derivados de piperazina; composición farmacéutica; que comprende a uno de los compuestos y uso de los compuestos en la preparación de medicamentos para el tratamiento y/o prevención de infecciones por protozoos, en forma particular para el tratamiento y/o prevención de la malaria.
BR112021018357A2 (pt) Forma cristalina de inibidor de fosfodiesterase, método de preparação para a mesma e uso da mesma
UY30982A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones.
BR112015031827A2 (pt) composto, processo para preparação de um composto, composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02/01/2019.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B350 Update of information on the portal [chapter 15.35 patent gazette]